Melodiol Global Health (AU:ME1) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Melodiol Global Health has reported substantial revenue growth with $21.6 million in FY23, marking a 148% increase, and a 91% increase to $4.4 million in Q1 FY24, signaling strong financial health and growth prospects. The company’s Mernova property has been independently valued between $10.4 million to $12.0 million, reflecting its significant investment in cannabis production facilities. Additionally, Melodiol has secured a convertible note facility up to $5 million with Harbour Capital Opportunities Fund to support marketing, sales, and potentially reduce existing debt.
For further insights into AU:ME1 stock, check out TipRanks’ Stock Analysis page.